Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax and Azacitidine in Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT06641414Phase 3Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jan 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Lisaftoclax + Azacitidine with Placebo + Azacitidine (2 arms). Primary endpoint: Overall Survival up to 5 years. Started Jan 2025; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06641414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641414.